Treatment of cytomegalovirus (CMV) retinitis with oral ganciclovir results in relatively low plasma concentrations of drug, which theoretically could cause more frequent viral resistance compared with intravenous (iv) ganciclovir. By use of a plaque-reduction assay to quantify phenotypic sensitivity to ganciclovir, virus isolates were studied from patients with CMV retinitis participating in four clinical trials of oral ganciclovir. Before treatment, 69% of patients were culture-positive but just 1.1% of patients yielded a resistant CMV, defined as a median inhibitory concentration (IC 50 ) 16 mM. On treatment, the first resistant isolate was recovered at 50 days. Overall, 3.1% of patients receiving iv ganciclovir and 6.5% of those taking oral ganciclovir shed resistant CMV (median ganciclovir exposures of 75 and 165 days, respectively). Since IC 50 s for clinical isolates increased proportionately with treatment duration, it is likely that viral resistance would be more frequent with longer treatment.
ganciclovir [9] , there has been concern that viral resistance might be more frequent after oral ganciclovir treatment. Therefore, we evaluated the in vitro sensitivity of CMV isolates collected during the conduct of four clinical studies of oral ganciclovir.
Materials and Methods
Clinical studies. CMV cultures were obtained from patients with CMV retinitis and AIDS participating in 1 of 4 clinical studies of oral ganciclovir conducted between October 1989 and October 1995 [6, [9] [10] [11] . One study enrolled patients with newly diagnosed retinitis who received iv ganciclovir treatment for a minimum of 3 weeks followed by maintenance treatment with either oral or iv ganciclovir [6] . The other 3 studies enrolled patients who had received prior treatment with iv ganciclovir for a minimum of 4 weeks. Ganciclovir was given at a dose of 3 g/day for 4-6 months (except for 6 persons who received higher oral doses). In 3 of the 4 studies, iv ganciclovir was the comparison drug given at a dose of 5 mg/kg daily.
CMV cultures. All study protocols specified that urine be cultured at designated time points, including at study entry, on-treatment study visits, and study termination. Additional cultures of blood and/or semen were to be performed if feasible. Virus isolates that were recovered were passaged in tissue culture, frozen in duplicate, and sent to the central phenotyping laboratory.
CMV resistance phenotyping. Quantification of in vitro sensitivity of CMV to ganciclovir was done by plaque reduction at a single laboratory, the Clinical Virology Research Laboratory, University of California San Francisco-Mt. Zion Medical Center. Virus titers of the isolates to be tested were increased by passage in human foreskin fibroblasts (MRHF, diploid fibroblasts). MRHF cells were grown in 24-well plates, and the test virus inoculum (50-100 pfu) was added to duplicate wells. The infected monolayers were washed with Puck's saline after incubation for 3 h at 37ЊC. MEM with 0.5% high-titered human CMV antibody and ganci- Figure 1 . Relationship between total days of ganciclovir exposure and in vitro antiviral sensitivity of cytomegalovirus (CMV) isolates to ganciclovir in patients with CMV retinitis and AIDS (data from 102 patients). ᭝ ϭ no prior ganciclovir treatment, Ⅵ ϭ oral ganciclovir, Ⅺ ϭ intravenous ganciclovir. Dashed line shows correlation. Symbols indicate ganciclovir treatment at time isolate was recovered. All patients on oral ganciclovir had previously received у3 weeks of intravenous ganciclovir treatment.
clovir at concentrations of 0, 1, 5, 10, 20, and 50 mM was added to each well. Plates were incubated at 37ЊC for 1 week. Each well was washed with Puck's saline, fixed with methanol, and stained with Wright-Giemsa. Plaques were counted with an inverted microscope. The concentration of drug causing a 50% reduction of plaques (median IC 50 ) was calculated by interpolation.
The definitions of "sensitive" and "resistant" utilized in this analysis were based upon current definitions used by the AIDS Clinical Trials Group (ACTG) [12] . However, the definitions used by the ACTG include a designation of "intermediate resistant" for CMV isolates with an IC 50 16.0 but !12 mM. Since 198% of CMV isolates recovered from treatment-naive patients have IC 50 s !6 mM [3, 4], we chose 6 mM as a more conservative threshold for defining antiviral resistance for CMV.
Statistical analyses. Total ganciclovir exposure was calculated as the number of days between first ganciclovir treatment after the diagnosis of CMV retinitis and the date of culture. Pearson's correlation coefficient was calculated to compare the ganciclovir exposure to the IC 50. Table 1 and figure 1 summarize the CMV culture and phenotyping results. A total of 189 positive cultures were identified from patients in the 4 studies. From these cultures, 102 CMV isolates (54% of positive cultures) were successfully recovered from the primary cultures, passaged, shipped to the central laboratory, and successfully phenotyped. Among the 64 pretreatment isolates tested for phenotype, 56 were recovered from urine (1 resistant isolate), 4 from blood, and 4 from other culture sources. Among the 38 isolates collected during treatment and phenotyped, 17 were from urine (6 resistant), 9 from blood (5 resistant), 8 from semen (1 resistant), and 4 from other culture sources (3 resistant).
Results
CMV culture and phenotyping results in previously untreated patients. Table 1 shows the CMV culture and phenotyping results from untreated patients with newly diagnosed CMV retinitis at study entry. Among 130 patients with newly diagnosed CMV retinitis cultured prior to ganciclovir treatment, 90 (69%) were shedding CMV; 64 of the 90 patients provided an isolate that was phenotyped. One untreated patient was shedding a resistant isolate ( figure 1, time 0) . The mean (median) IC 50 of the 64 isolates collected before treatment was 2.38 (2.15) mM (range, 0.08-13.9). After ganciclovir treatment was begun, the rate of CMV shedding was reduced to 18% of cultured patients. After a median treatment of 21 days, 1 of 9 isolates phenotyped showed resistance.
CMV culture and phenotyping results in previously treated patients. Among the 497 cultured patients who entered a study after prior ganciclovir treatment (median treatment, 69 days), 29 patients (6%) were culture-positive at study enrollment and isolates were phenotyped from 12 of the 29. Five of the 12 phenotyped isolates showed resistance (table 1). With continued study treatment with iv or oral ganciclovir (median drug exposure, 172 days), 12% of patients were culture-positive, and 9 of 17 isolates phenotyped showed resistance.
Duration of ganciclovir treatment and virus IC 50 . Figure 1 shows the IC 50 of each tested CMV isolate from all patients as a function of total ganciclovir exposure (iv and oral) for a median time on treatment of 108 days. There was a positive correlation between the total duration of ganciclovir exposure at the time the isolate was cultured and the isolate's IC 50 ( , ; figure 1 ). Isolates with IC 50 s 16 mM were 2 r ϭ 0.585 P ! .001 first detected by day 50 of treatment.
Viral resistance with iv versus oral ganciclovir treatment.
To compare the frequency of resistance associated with the two routes of drug administration, we phenotyped 32 CMV isolates collected after patients were assigned to iv or oral ganciclovir formulation (table 2). (Note that these groups were not randomized.) Although the mean and median IC 50 s were somewhat higher in the oral treatment group, the proportion of patients who shed a resistant isolate was similar in the two groups, even though the patients treated orally had about twice the cumulative duration of exposure to ganciclovir than patients treated iv.
Discussion
Because it is possible to test phenotypic resistance only if a CMV isolate can be recovered from a patient and cultured, estimates of the overall frequency of resistant CMV must be based upon the premise that persons who are not shedding CMV do not harbor a clinically significant resistant strain. The frequency of resistance can then be approximated by multiplying the proportion of persons shedding CMV by the proportion of those shedding a resistant CMV strain, as suggested by Drew et al. [3] . In the present study, before ganciclovir treatment, 69% of patients with CMV retinitis were CMV culture-positive and 1.6% shed a resistant virus. Thus, the pretreatment frequency of resistance was 1.1% (69% frequency of shedding ϫ 1.6% of isolates resistant).
During treatment with ganciclovir, the overall percentage of patients who were culture-positive decreased, but the proportion of isolates that were resistant increased as shown diagrammatically in figure 2 . The estimated frequency of resistance among patients treated only with iv ganciclovir was 3.1% (7% % of isolates resistant). The estimated frequency shedding ϫ 44 of resistance among patients treated with oral ganciclovir was 6.5% (13% % of isolates resistant). Thus, conshedding ϫ 50 cerns about the use of oral ganciclovir resulting in increased CMV resistance are not supported by our data, at least during the first 6 months of therapy.
There are several limitations to the present analysis that may affect interpretation of the results. First, the estimated frequency of resistance was based on the assumption that persons who are not CMV culture-positive do not harbor a clinically significant resistant strain. Second, estimations of the frequency of CMV shedding or viremia were a function of how often patients were cultured for CMV in these studies. The observed resistance rates may have been higher had the patients been cultured more frequently or had the trials been longer. Third, the CMV isolates evaluated for in vitro sensitivity were recovered from a variety of tissues and body fluids; however, these sources may not reflect CMV phenotypes in the eye or other CMV-infected tissues. Last, CMV cultures may consist of a mixture of phenotypes, and those that predominate during passage and preparation for sensitivity testing may not represent the phenotypes that predominate in vivo.
Despite these limitations, our results agree with those reported by other investigators [3, 4] , including those of Jabs et al. [5] , who recently reported on ganciclovir resistance in patients with CMV retinitis. These investigators estimated the frequency of resistance in the urine to be 1.5%, 1.5%, and 7.3% after 3, 6, and 9 months of iv ganciclovir, respectively. Blood cultures provided higher estimates of resistance of 3.8%, 10.0%, and 26.4%, respectively.
Our analysis, incorporating results from 4 clinical studies, confirms that resistance to ganciclovir emerges during treatment of CMV infections with either iv or oral ganciclovir. Viral resistance to ganciclovir appears to increase with duration of drug exposure, and we expect that the frequency of resistance seen at 9 or 12 months of treatment would exceed the frequencies we observed after 3-6 months. Nonetheless, treatment with oral ganciclovir does not appear to result in a markedly increased frequency of viral resistance compared to treatment with iv ganciclovir.
